- Home
- Who We Are
About Us
Qu Biologics has attracted a team of life sciences professionals who are leaders in their respective fields.
- What We Do
What We Do
Qu Biologics’ SSIs restore innate immune function and reverse the chronic inflammation underlying many conditions such as cancer and immune-related disease.
- Clinical Trials
Clinical Trials
Investigational treatment QBECO SSI is an immunotherapy aimed at restoring normal immune function to reverse the chronic inflammation underlying Crohn’s disease.
- Partner With Us
Partner With Us
To gain a better understanding of the root causes of disease and the potential benefits of novel immunotherapies, Qu Biologics has a number of university research collaborations.
- Qu In The News
- Careers
Careers
Join a team of innovators who have a passion to make a difference. In a short time, our ambitious team has achieved a number of major milestones and we have many big goals ahead.
- Contact Us
News
Positive Signals for Endoscopic and Histologic Response in Patients with Crohn’s Disease Treated with Qu Biologics’ QBECO
Vancouver, British Columbia – January 4, 2021 – Qu Biologics Inc., a private clinical stage biopharmaceutical company developing Site Specific Immunomodulators (SSIs), a novel platform of immunotherapies designed to restore innate immune function, is pleased to report positive signs of clinical, endoscopic and histologic response in subjects participating in Stage 1 of their Phase 2 […]
READ MORE >Qu Biologics Receives Funding for COVID-19 Prevention/Treatment Research with Qu’s Novel Immunotherapy Platform
VANCOUVER, British Columbia, Dec-18-2020 (GLOBE NEWSWIRE) — Qu Biologics Inc., a private clinical stage biopharmaceutical company developing Site Specific Immunomodulators (SSIs), a novel platform of immunotherapies designed to restore innate immune function, is pleased to announce it is receiving advisory services and research and development funding from the National Research Council of Canada Industrial Research […]
READ MORE >Qu Biologics Completes $8M Financing
Vancouver, British Columbia – Dec-9-2020 (Global Newswire) – Qu Biologics Inc., a private clinical stage biopharmaceutical company developing Site Specific Immunomodulators (SSIs), a novel platform of immunotherapies designed to restore innate immune function, is pleased to announce an oversubscribed $8 million financing. With the proceeds, Qu Biologics will complete stage 1 of the RESTORE Phase […]
READ MORE >Qu Biologics is pleased to announce the appointment of Karn Manhas to Qu’s Board of Directors
VANCOUVER, British Columbia — Aug-24-2020 (GLOBE NEWSWIRE) — Qu Biologics Inc., a biopharmaceutical company developing Site Specific Immunomodulators (SSIs), a novel platform of immunotherapies designed to restore innate immune function, is pleased to announce that Karn Manhas, Founder and CEO of Terramera and agtech industry pioneer, has joined Qu Biologics’ Board of Directors. Karn Manhas, […]
READ MORE >Qu Biologics Initiates Phase 2 Study to Assess Activation of Anti-cancer Immune Response in Colon Cancer
Vancouver, British Columbia – August-18-2020 (GlobalNews Wire) – Qu Biologics Inc., a biopharmaceutical company developing Site Specific Immunomodulators (SSIs), a novel platform of immunotherapies designed to restore innate immune function, is pleased to announce approval from the Israeli Ministry of Health to proceed with their clinical trial of QBECO SSI in patients with colorectal cancer. […]
READ MORE >Qu Biologics publishes landmark studies showing cells of the innate immune system can be directed to target organ sites to prevent and clear pathology and infection
VANCOUVER, British Columbia – Apr-6-2020 (GLOBE NEWSWIRE) – Qu Biologics Inc. (Qu), a biopharmaceutical company developing Site Specific Immunomodulators (SSIs), a unique platform of microbial-based immunotherapies designed to restore the body’s innate immune system, has published for the first time the basis of their first-in class therapy. The series of studies, published this week in […]
READ MORE >Qu Biologics Completes Enrollment in First Stage of Phase 2 Clinical Trial in Moderate to Severe Crohn’s Disease
VANCOUVER, British Columbia – Dec. 18, 2019 (GLOBE NEWSWIRE) — Qu Biologics Inc., a biopharmaceutical company developing Site Specific Immunomodulators (SSIs), a novel immunotherapy platform designed to restore innate immune function, is pleased to announce the completion of enrollment for the first stage of the RESTORE clinical trial, “A Phase 2, Multi-center, Randomized, Double-Blind, Placebo-Controlled […]
READ MORE >Qu Biologics publishes potentially paradigm-shifting results of their first randomized-placebo controlled trial for the treatment of Crohn’s disease
Vancouver, British Columbia – July 23rd, 2019 – Qu Biologics Inc. (Qu), a biopharmaceutical company developing Site Specific Immunomodulators (SSIs), a unique platform of microbial-based immunotherapies designed to restore the body’s innate immune system, is pleased to report that the results of their first randomized-placebo controlled trial (RCT) in patients with moderate-to-severe Crohn’s disease (CD) […]
READ MORE >Qu Biologics enrolls the first patient in new Phase 2 Crohn’s disease clinical trial
Vancouver, British Columbia – July 25, 2018 – Qu Biologics Inc., a biopharmaceutical company developing Site Specific Immunomodulators (SSIs), a novel platform of immunotherapies designed to restore innate immune function, is pleased to announce that the first patient in the RESTORE Phase 2 clinical trial for patients with moderate to severe Crohn’s disease has been […]
READ MORE >Crohn’s disease clinical trial – Now enrolling
Qu Biologics is now recruiting Canadian residents to participate in the first stage of a Phase 2 clinical trial of QBECO SSI in the treatment of adults living with moderate to severe Crohn’s disease. The aim of this trial is to further establish the safety and efficacy of the investigational drug QBECO SSI for the […]
READ MORE >